Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-164 in Advanced Gastrointestinal Cancers
NCT03449030Phase 1Terminated
- Sponsor
- Millennium Pharmaceuticals
- Start
- Apr 2018
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TAK-164 in gastrointestinal cancer, colorectal cancer (CRC), gastric cancer (GC) and 3 more (3 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Number of Participants With Dose-limiting Toxicities, Percentage of Participants With Adverse Events up to 22 months and 1 more. Started Apr 2018; status: terminated.
02
Drugs
TAK-164
03
Conditions
gastrointestinal cancercolorectal cancer (CRC)gastric cancer (GC)esophageal cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03449030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03449030.